US88023B1035
© BusinessWire
18.11.2025
TEM
LISTED
NASDAQ
Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET.
The live webcast...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2025
TEM
LISTED
NASDAQ
Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the development of inno...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
TEM
LISTED
NASDAQ
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
04.11.2025
TEM
LISTED
NASDAQ
Tempus Reports Third Quarter 2025 Results
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025.
Revenue grew 84.7% year-over-year to $334.2 million in the third quarter of 2025
Gross profit reached $209.9 million in the third quarter of 20...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
28.10.2025
TEM
LISTED
NASDAQ
Tempus to Participate in the Stifel 2025 Healthcare Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference on Thursday, November 13 in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:00 AM ET.
The live webcast will be availab...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
TEM
LISTED
NASDAQ
Tempus to Report Third Quarter 2025 Financial Results on November 4
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET.
The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Office...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
TEM
LISTED
NASDAQ
Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity
News Preview
Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in Genetics in Medicine (GIM), the official journal of the American College of Medical Genetics and Genomics (ACMG). The ACMG is a national organization bringing together experts in medical...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
TEM
LISTED
NASDAQ
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjuga...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
TEM
LISTED
NASDAQ
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany.
“We’re sharing research at ESMO Congress 2025, inclu...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
TEM
LISTED
NASDAQ
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in s...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
TEM
LISTED
NASDAQ
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
News Preview
Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) and a pioneer in clinical genomic testing, today announced an enhancement to the Ambry CARE Program® (CARE), Ambry’s digital platform that streamlines cancer risk assessment and genetic testing workflows. The update integrates breast density into the Tyrer-Cuzick (TC) b...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
TEM
LISTED
NASDAQ
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
11.09.2025
TEM
LISTED
NASDAQ
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enh...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
TEM
LISTED
NASDAQ
Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company’s PurIST® algorithmic diagnostic. The study provides the largest real-world evidence to date supporting the integration of...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
TEM
LISTED
NASDAQ
Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform
News Preview
Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) today announced a notable expansion of their longstanding collaboration. Northwestern Medicine will be the first health system to integrate David, Tempus’ generative-AI clinical co-pilot, within its electronic health record (EHR) platform for its clinical care team. The expanded collaboration...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
TEM
LISTED
NASDAQ
Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference. The conference will take place September 8-10 in New York City. Eric Lefkofsky, Founder and CEO of Tempus, and Jim Rogers, Chief Financial Offi...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2025
TEM
LISTED
NASDAQ
Tempus Announces the Acquisition of Paige
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
TEM
LISTED
NASDAQ
Tempus to Report Second Quarter 2025 Financial Results on August 8
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company’s quarterly earnings will be released the same day.
The call will f...
Themefolio
Profiler
Peergroup
© BusinessWire
16.07.2025
TEM
LISTED
NASDAQ
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left v...
Themefolio
Profiler
Peergroup
© BusinessWire
08.07.2025
TEM
LISTED
NASDAQ
Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Since its launch in 2024, Tempus Next has screened thousands of patients across its network of provider sites, helpi...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
TEM
LISTED
NASDAQ
Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
News Preview
Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $650 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualif...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
TEM
LISTED
NASDAQ
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
News Preview
Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $400 million aggregate principal amount of Convertible Senior Notes due in 2030 (the “Notes”) in a private placement (the “Off...
Themefolio
Profiler
Peergroup
© BusinessWire
27.06.2025
TEM
LISTED
NASDAQ
Deadline Alert: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming August 12, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”...
Themefolio
Profiler
Peergroup
© BusinessWire
26.06.2025
TEM
LISTED
NASDAQ
Deadline Approaching: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming August 12, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”).
IF YOU ARE AN INVESTOR WHO...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
TEM
LISTED
NASDAQ
Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
News Preview
Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of the Ambry CARE Program® (CARE) for hereditary cancer risk assessment has been published in the Journal of the National Comprehensive Cancer Network. T...
Themefolio
Profiler
Peergroup
© BusinessWire
24.06.2025
TEM
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Perio...
Themefolio
Profiler
Peergroup
© BusinessWire
24.06.2025
TEM
LISTED
NASDAQ
Law Offices of Howard G. Smith Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). Tempus investors have until August 12, 2025 to file a lead plaintiff motion.
IF YO...
Themefolio
Profiler
Peergroup
© BusinessWire
23.06.2025
TEM
LISTED
NASDAQ
Law Offices of Frank R. Cruz Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). Tempus investors have until August 12, 2025 to file a lead plaintiff motion.
IF...
Themefolio
Profiler
Peergroup
© BusinessWire
20.06.2025
TEM
LISTED
NASDAQ
Securities Fraud Investigation Into Tempus AI, Inc. (TEM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON TEMPUS AI, I...
Themefolio
Profiler
Peergroup
© BusinessWire
20.06.2025
TEM
LISTED
NASDAQ
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-...
Themefolio
Profiler
Peergroup
© BusinessWire
20.06.2025
TEM
LISTED
NASDAQ
Tempus AI, Inc. (TEM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSU...
Themefolio
Profiler
Peergroup
© BusinessWire
19.06.2025
TEM
LISTED
NASDAQ
Securities Fraud Investigation Into Tempus AI, Inc. (TEM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON TEMPUS AI, INC. (TEM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVE...
Themefolio
Profiler
Peergroup
© BusinessWire
17.06.2025
TEM
LISTED
NASDAQ
Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in TD Cowen's/Securities' 4th Annual Tools/Dx Revolution conference. The event is taking place on June 22 - 25, 2025, in Dana Point, California. Jim Rogers, Chief Financial Officer of Tempus, will join the...
Themefolio
Profiler
Peergroup
© BusinessWire
17.06.2025
TEM
LISTED
NASDAQ
TEMPUS AI SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May...
Themefolio
Profiler
Peergroup
© BusinessWire
16.06.2025
TEM
LISTED
NASDAQ
TEM Investors Have Opportunity to Lead Tempus AI, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. (“Tempus” or “the Company”) (NASDAQ: TEM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investor...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
TEM
LISTED
NASDAQ
Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation i...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
TEM
LISTED
NASDAQ
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest additi...
Themefolio
Profiler
Peergroup
© BusinessWire
01.06.2025
TEM
LISTED
NASDAQ
Introducing Tempus One in the EHR with Integrated Guidelines
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expan...
Themefolio
Profiler
Peergroup
© BusinessWire
31.05.2025
TEM
LISTED
NASDAQ
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learni...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
TEM
LISTED
NASDAQ
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 - June 3 in Chicago, Illinois. Tempus will p...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
TEM
LISTED
NASDAQ
Tempus AI, Inc. (NASDAQ: TEM) Securities Fraud Investigation; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
News Preview
Shares of Tempus AI, Inc. fell over 19% in intraday trading on Wednesday, May 28, 2025, after Spruce Point Capital Management published a report alleging that Tempus AI is engaging in “aggressive and suspicious accounting practices,” and the company’s leaders are “connected to troubling financial restatements and SEC-charged fraud allegations.” Gi...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
TEM
LISTED
NASDAQ
TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tempus AI, Inc. (“Tempus” or “the Company”) (NASDAQ: TEM) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclo...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
TEM
LISTED
NASDAQ
Rosen Law Firm Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation – TEM
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public.
So What: If you purchased Tempus AI securities y...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
TEM
LISTED
NASDAQ
A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its participation in almost 1,500 research projects in just the last ten years. This milestone highlights Tempus’ ongoing commitment to accelerating scientific discovery and delivering data-driven insights...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
TEM
LISTED
NASDAQ
New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis
News Preview
Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG). The study reveals the potentially transformative impact of Ambry Genetics...
Themefolio
Profiler
Peergroup
© BusinessWire
21.05.2025
TEM
LISTED
NASDAQ
Tempus to Present at the William Blair 45th Annual Growth Stock Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference. The event will take place from June 3-5 in Chicago, IL.
Jim Rogers, Chief Financial Officer of Tempus, will present on June 5. A live audio webcas...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
TEM
LISTED
NASDAQ
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
TEM
LISTED
NASDAQ
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years,...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
TEM
LISTED
NASDAQ
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal,...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
TEM
LISTED
NASDAQ
Tempus Reports First Quarter 2025 Results
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025.
Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025
Quarterly gross profit increased 99.8% year-over-year, reachi...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
TEM
LISTED
NASDAQ
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcr...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
TEM
LISTED
NASDAQ
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edg...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
TEM
LISTED
NASDAQ
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a no...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
TEM
LISTED
NASDAQ
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus’ proprietary approach to novel target identification that integrates real-world patient data (RWD) with human...
Themefolio
Profiler
Peergroup
© BusinessWire
25.04.2025
TEM
LISTED
NASDAQ
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus resear...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
TEM
LISTED
NASDAQ
Tempus to Report First Quarter 2025 Financial Results on May 6
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day.
The call will featu...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
TEM
LISTED
NASDAQ
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can be use...
Themefolio
Profiler
Peergroup
© BusinessWire
18.04.2025
TEM
LISTED
NASDAQ
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in e...
Themefolio
Profiler
Peergroup
© BusinessWire
29.03.2025
TEM
LISTED
NASDAQ
Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus is presen...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
TEM
LISTED
NASDAQ
Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7-10, 2025.
Tempus’ Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Wednesday, April 9. A...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
